$10.65
0.37% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US15102K1007
Symbol
CELC

Celcuity Inc. Stock price

$10.65
+0.20 1.91% 1M
-2.13 16.67% 6M
-2.44 18.64% YTD
-6.15 36.61% 1Y
+4.95 86.84% 3Y
+1.36 14.64% 5Y
-3.64 25.47% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.04 0.37%
ISIN
US15102K1007
Symbol
CELC
Sector
Industry

Key metrics

Market capitalization $403.28m
Enterprise Value $296.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.65
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-126.91m
Free Cash Flow (TTM) Free Cash Flow $-102.47m
Cash position $205.69m
EPS (TTM) EPS $-3.03
P/E forward negative
Short interest 6.39%
Show more

Is Celcuity Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Celcuity Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Celcuity Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Celcuity Inc. forecast:

Buy
100%

Financial data from Celcuity Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.14 0.14
8% 8%
-
-0.14 -0.14
8% 8%
-
- Selling and Administrative Expenses 11 11
82% 82%
-
- Research and Development Expense 116 116
65% 65%
-
-127 -127
67% 67%
-
- Depreciation and Amortization 0.14 0.14
8% 8%
-
EBIT (Operating Income) EBIT -127 -127
67% 67%
-
Net Profit -127 -127
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Celcuity Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celcuity Inc. Stock News

Neutral
Seeking Alpha
6 days ago
Celcuity Inc. (NASDAQ:CELC ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Apoorva Chaloori - ICR Healthcare Brian Sullivan - Chief Executive Officer and Co-Founder Vicky Hahne - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Tara Bancroft - TD Cowen Gil Blum - Needham and Company Oliver McCammon - LifeSci Capital Operator Good af...
Neutral
GlobeNewsWire
6 days ago
The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in the fourth quarter of 2025 VIKTORIA-2 Phase 3 trial remains on track to dose its fi...
Neutral
GlobeNewsWire
14 days ago
MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to...
More Celcuity Inc. News

Company Profile

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Head office United States
CEO Brian Sullivan
Employees 87
Founded 2012
Website www.celcuity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today